It is made available under a CC-BY-NC-ND 4.0 International license .

- 1 Predictors of Response to Cardiac Resynchronization Therapy in
- 2 Pediatric and Congenital Heart Disease Patients
- 3
- 4 Authors
- 5 Henry Chubb MA MBBS PhD^{1,2}, Douglas Mah MD³, Maully Shah MD⁴, Kimberly Y Lin MD⁴, David
- 6 Peng MD⁵, Benjamin W Hale MD^{5,6}, Lindsay May MD⁷, Susan Etheridge MD⁷, William Goodyer¹,
- 7 Scott R Ceresnak MD¹, Kara S Motonaga MD¹, David N Rosenthal MD¹, Christopher S Almond
- 8 MD MPH¹, Doff B McElhinney MD^{1,2}, Anne M Dubin MD¹
- 9

10 Author Affiliations

- ¹Division of Pediatric Cardiology, Department of Pediatrics, Stanford University, CA, USA
- 12 ²Division of Pediatric Cardiothoracic Surgery, Department of Cardiothoracic Surgery, Stanford
- 13 University, CA, USA
- ³ Department of Cardiology, Boston Children's Hospital; Department of Pediatrics, Harvard
- 15 Medical School; Boston MA, USA
- ⁴ Department of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA
- ⁵ Department of Cardiology, CS Mott Children's Hospital, University of Michigan , Ann Arbor,
- 18 MI, USA
- ⁶ Department of Pediatrics, Stead Family Children's Hospital, Iowa City, IA
- ⁷ Department of Cardiology, Primary Children's Hospital, University of Utah, Salt Lake City, UT,
- 21 USA
- 22

23 Corresponding Author

- 24 Henry Chubb, Clinical Associate Professor, Division of Pediatric Cardiology, Stanford University
- 25 School of Medicine, 750 Welch Road, Stanford, CA 94304
- 26 mhchubb@stanford.edu
- 27
- 28 Total Word Count

It is made available under a CC-BY-NC-ND 4.0 International license .

- 29 4873 (including manuscript body, references and figure legends)
- 30
- 31 Disclosure Statements
- 32 The authors would like to declare the following relationships with industry
- 33
- 34 Henry Chubb None
- 35 Douglas Mah None
- 36 Maully Shah- Medtronic Inc- consultant
- 37 Kimberly Lin- None
- 38 David Peng- None
- 39 Benjamin Hale- None
- 40 Lindsay May- None
- 41 Susan Etheridge- None
- 42 William Goodyer- None
- 43 Scott Ceresnak- None
- 44 Kara Motonaga- None
- 45 David Rosenthal- None
- 46 Christopher Almond- None
- 47 Doff McElhinney- Medtronic Inc- Proctor and Consultant
- 48 Anne Dubin- None
- 49
- 50 Funding
- 51 None
- 52
- 53 Keywords
- 54 Cardiac resynchronization therapy; Congenital heart disease; Cardiac Failure; Pediatric;
- 55 Predictors of Response; Dyssynchrony

56 Abstract

57 Background:

- 58 Cardiac resynchronization therapy (CRT) is an important therapeutic option in selected pediatric
- 59 and congenital heart disease (CHD) patients with reduced systemic ventricular (SV) ejection
- 60 fraction (EF). However, the identification of optimal responders is challenging.
- 61

62 **Objective**:

- 63 To identify predictors of response to CRT in children and CHD patients at 5 large quaternary
- 64 referral centers.
- 65

66 Methods:

- 67 Patients were <21 years or had CHD; had SVEF <45%; symptomatic heart failure; and significant
- 68 electrical dyssynchrony prior to CRT. Primary outcome was defined as an ordinal response at
- 69 6/12months: (1) Improved EF [≥5%], (2) Unchanged SVEF, (3) Worse SVEF. Secondary outcome
- 70 utilized a propensity score-matched control cohort. Response to CRT was defined using
- 71 longitudinal trajectory of SVEF up to latest follow-up.
- 72

73 Results:

- 74 In total, 167 eligible CRT recipients were identified across the 5 centers. 150 had
- 75 comprehensive data at 6/12months: 96(64%) with improved SVEF, 26(17%) unchanged,
- 76 28(19%) worsened. Mean increase in SVEF was 11% [IQR 3-21%]. On univariable ordinal
- 77 regression, lower SVEF (p=0.013), biventricular circulation (p=0.022), systemic LV (p=0.021), and
- 78 conduction delay to lateral wall of SV (p=0.01) were associated with positive response.
- 79
- 80 For assessment of secondary outcome, 324 controls were identified. Mean follow-up 4.2(±3.7)
- 81 yrs. Almost all subgroups demonstrated improved SVEF trend with CRT, except those with
- 82 systemic RV (p=0.69) or without prior single site pacemaker (p=0.20).
- 83

84 **Conclusion**:

- 85 CRT in children and CHD patients frequently results in an improvement in SVEF. Those with
- 86 lower SVEF, conduction delay to lateral wall of the SV and those with systemic LV are most
- 87 likely to respond.
- 88
- 89

It is made available under a CC-BY-NC-ND 4.0 International license .

90 Condensed Abstract

- 91 Cardiac resynchronization therapy (CRT) is an important therapeutic option in selected pediatric
- 92 and congenital heart disease (CHD) patients with reduced systemic ventricular (SV) ejection
- 93 fraction (EF). However, the identification of optimal responders is challenging.
- 94
- 95 In this multicenter study, pediatric and CHD CRT recipients with heart failure and EF<45% were
- 96 identified. The primary outcome was change in EF at 6/12months. Those with lower baseline
- 97 SVEF, conduction delay to lateral wall of the SV and/or systemic LV were most likely to respond
- to CRT. When compared to propensity score-matched controls, the CRT groups also
- 99 demonstrated a significantly better long-term EF trajectory.
- 100
- 101

102 Key Words

- 103 Cardiac Resynchronization Therapy
- 104 Pediatric
- 105 Heart Failure
- 106 Congenital Heart Disease
- 107 Cardiac Transplant
- 108 Electrical Dyssynchrony
- 109
- 110 Abbreviations List
- 111 CHD: Congenital Heart Disease
- 112 CRT: Cardiac Resynchronization Therapy
- 113 DCM: Dilated Cardiomyopathy
- 114 EF: Ejection Fraction
- 115 HF: Heart Failure
- 116 HR: Hazard Ratio
- 117 ICD: Implantable Cardioverter Defibrillator
- 118 LV: Left Ventricle
- 119 NYHA: New York Heart Association
- 120 PSM: Propensity Score-Match
- 121 QRSd: QRS Duration
- 122 RV: Right Ventricle
- 123 SV: Systemic Ventricle
- 124

It is made available under a CC-BY-NC-ND 4.0 International license .

125 Introduction

126 Cardiac resynchronization therapy (CRT) is a treatment modality widely employed for patients 127 with significant systemic ventricular (SV) dysfunction and evidence of electrical dyssynchrony. However, evidence for the use of this important treatment is relatively limited in children and 128 129 congenital heart disease (CHD) patients as all prospective randomized trials of CRT have specifically excluded these subjects.¹⁻⁶ None the less, retrospective studies and meta-analysis 130 have clearly demonstrated that many children and CHD patients may benefit from CRT in terms 131 of improvement in systemic ventricular function.⁷⁻¹¹ Furthermore, we have recently 132 133 demonstrated in a multicenter study that there is a strong association of CRT with survival in a broad group of patients with systemic ventricular ejection fraction (SVEF)<45%, significant 134 electrical dyssynchrony and cardiac failure symptoms.¹² However, the factors that identify 135 136 those children and CHD subjects that are most likely to respond to CRT have not been defined. 137 The need to identify the pediatric and CHD groups that are most likely to respond to CRT is 138 particularly pertinent in the context of the increased technical challenges of CRT implant 139

140 procedures compared to adults with structurally normal hearts. The implants may be highly

141 complex and frequently require repeat sternotomy. In adults without CHD, the presence of left

142 bundle branch block (LBBB), female sex, and longer QRS duration (QRSd) have been identified

143 to be the most robust predictors of response.¹³ In the pediatric/CHD patients, though,

144 QRSd>150msec and LBBB are rarely seen.¹⁴

145

In a population as heterogenous as that of children and CHD subjects with systemic ventricular
systolic failure, there are many fundamental pathophysiological differences between patients
that are likely to play a role in response to CRT. However, the largest retrospective studies of
these patients have not concurred as to whether there are distinct subgroups that are more or
less likely to respond. Key subgroups for assessment include those with and without prior
ventricular pacing, those with and without CHD and then, within CHD, those with and without a
biventricular circulation and systemic LV.^{11, 15}

It is made available under a CC-BY-NC-ND 4.0 International license .

154 We hypothesized that the assessment within a larger multicenter CRT cohort would be

155 sufficiently powered to identify key predictors of response to CRT within these patient groups.

156 Given the challenge in defining response in these heterogenous morphologies, we chose to use

157 two main outcomes. The first was medium term (6-12month) change in SVEF, referenced to the

- 158 patient baseline prior to CRT. The second utilized a matched control group (without CRT) to
- 159 compare the longitudinal impact of CRT.
- 160

161 Methods

162 Data collection

This was a multicenter retrospective study. Patient data were de-identified and electronically
transferred to the coordinating center through a secure web- based server (REDCap [Research
Electronic Data Capture], Vanderbilt University, Nashville, TN). The study was approved by
institutional review board (IRB) at the co-ordinating center (Stanford University, IRB-45389),
with local IRB and data use agreement approval obtained at each center. The survival outcomes
of this cohort have recently been reported.¹²

169

170 Study population

171 All pediatric (<21years) and/or CHD patients who underwent CRT at five large quaternary 172 referral institutions (Lucile Packard Children's Hospital and Stanford Healthcare, Boston 173 Children's Hospital, Children's Hospital of Philadelphia, Primary Children's Hospital (University 174 of Utah), and CS Mott Children's Hospital (University of Michigan)) between Jan 1, 2004 and Jan 175 1, 2018 were identified. CRT was defined as a multi-site ventricular pacing system implanted 176 with at least one pacing lead to the systemic ventricle (SV). CHD was defined as any congenital 177 heart defect other than isolated bicuspid aortic valve, patent foramen ovale or patent ductus 178 arteriosus. Subjects were included if, at the time of CRT implant, they had systemic SVEF <45%; 179 symptomatic heart failure [defined as American Heart Association Stage C or D]; and significant 180 electrical dyssynchrony [defined as either a QRSd z-score≥3 or, in paced patients, a ventricular 181 pacing burden (Vp) \geq 40%] (Figure 1). Subjects were excluded if they had Eisenmenger 182 syndrome, a current ventricular assist device, previous heart transplant or weight <4kg.

It is made available under a CC-BY-NC-ND 4.0 International license .

183

Control subjects were defined as pediatric and/or CHD patients who never received CRT and who met the same inclusion and exclusion criteria at an outpatient clinical encounter within the same time period. Controls were also excluded if there was a documented, planned, intervention for heart failure, such as alleviation of systemic outflow tract obstruction or ablation procedure for high ventricular ectopy burden. However, controls became eligible for enrollment once the intervention had been performed, and, similarly, once weight was >4kg, provided all inclusion criteria continued to be met.

191

192 Identification of Subjects, Enrollment and Follow-Up

193 CRT subjects were identified via the institutional pacing databases. For control subjects, a 194 comprehensive screening cohort with low SVEF and electrical dyssynchrony was identified by 195 cross-referencing the institutional echocardiographic, ECG and pacing databases. All patients 196 with both an estimated SVEF <45% and QRSd z-score ≥3 were selected for individual review for 197 fulfillment of inclusion and exclusion criteria. Ventricular pacing-related dyssynchrony was identified via cross-referencing the echocardiographic database with the temporally matched 198 199 device interrogation report to identify Vp >40% and SVEF <45%. Enrollment for CRT subjects was on the day of CRT implantation. Enrollment for control subjects was at the first outpatient 200 201 appointment where all inclusion criteria were met.

202

Longitudinal assessments of all patients were collected at follow-up closest to 6 months, 1 year,
and 5 years post enrollment, and latest follow-up. Precise date of assessment, number of heart

failure medications, NYHA class, SVEF, QRSd, height and weight were obtained at each

206 timepoint.

207

208 Electrical Assessment

209 QRSd was measured in leads II and V_5 and averaged. Strict left bundle branch block (LBBB) was

210 defined using adaptation of the criteria outlaid by Strauss et al, and was assessed on the surface

211 ECG without reference to underlying cardiac anatomy.¹⁶ Right bundle branch block (RBBB) was

It is made available under a CC-BY-NC-ND 4.0 International license .

- defined according to the Minnesota Code criteria (7-2-1). QRSd z-score equivalent to ≥120ms
- 213 (z-score \geq +2.3) was used along with the published RBBB criteria.¹⁷
- 214

215 Conduction delay to the lateral wall of the SV (CDtoLWSV) was defined as those patients with

- 216 strict criteria LBBB and SV (which could be morphological left or right ventricle) in the
- 217 conventional left ventricular (LV) position, or a RBBB and SV in conventional right ventricular
- 218 (RV) position. Those with complex ventricular arrangement (such as dextrocardia) therefore
- could not be defined as CDtoLWSV, regardless of the ECG morphology.
- 220

221 Radiographic Assessment

222 Separation of the ventricular pacing leads was assessed on the first biplane chest x-ray

- following CRT implant (Figure 1). Unipolar pacing was rarely employed, and for those with
- 224 multiple poles (eg epicardial bipolar leads), the mid-point of all poles was taken for each
- ventricular lead. Total distance in 3-dimensions, assuming orthogonal alignment of the two
- imaging planes, was indexed to the thoracic cavity width, creating a Lead Separation Ratio
- 227 (LSR).
- 228

229 Echocardiographic Assessment

- 230 Baseline echocardiographic measurements were made on the final comprehensive
- 231 echocardiogram prior to CRT implant. SVEF for the systemic RV was calculated from the
- 232 fractional area change (RVFAC), using the estimation RVEF = 10.7 + (0.87*RVFAC).¹⁸
- 233

234 First Definition of Response: Medium-Term Change in SVEF from Baseline

There is no clear consensus on the optimal marker of response to CRT, particularly in the CHD

- 236 population where many patients have differing systemic ventricular morphology. Most non-
- 237 CHD studies of CRT response have used a ≥15% reduction in LVESV as a threshold, but such a
- 238 measure is not universally applicable in patients with mixed ventricular anatomy. ^{13, 19} Studies
- 239 of CRT including CHD subjects have historically used a variety of measures of change in SV

It is made available under a CC-BY-NC-ND 4.0 International license .

- 240 ejection fraction EF.^{7-9, 11} A primary outcome of an echocardiographic functional response was
- 241 therefore defined as follows:
- 242 1. Worsened: fall in SVEF at follow-up following CRT implant
- 243 2. No change: absolute increase in SVEF of between 0% and 5%
- 244 3. Improvement: absolute increase in SVEF of ≥5%
- 245
- 246 Other studies have used a proportional increase in SVEF as a marker of response, with the
- 247 rationale that larger (but sometimes less clinically significant) changes may occur in patients
- 248 with higher baseline EF, potentially biasing results. Therefore, a proportional response was also
- 249 defined in order to further enable comparison between studies:
- 250 1. Worsened: fall in SVEF at follow-up following CRT implant
- 251 2. No change: proportional increase in SVEF of between 0% and 10%
- 252 3. Improvement: proportional increase in SVEF of ≥10%
- 253

254 Echocardiographic parameters were assessed at closest follow-up to 6 months post implant and

- 255 12 months post implant for all patients. Follow-up at both time points was available in many,
- but not all, patients. Following sensitivity analyses for those with assessments recorded at both
- 257 6 and 12 months (see results), the average of the two measurements was used in order to
- 258 mitigate for variations in time to assessment.

259

- 260 Second Definition of Response: Longitudinal Trends with and without CRT
- 261 The identification of propensity score matched controls has been described in detail in a prior
- 262 publication from our group,¹² and the tables detailing the baseline parameters of the
- 263 unmatched and matched cohorts meeting inclusion criteria for each analysis are included in the
- 264 Data Supplement. Response to CRT was defined as a significant positive impact of CRT upon
- 265 longitudinal modelling of the long-term parameters (see statistical details below).

It is made available under a CC-BY-NC-ND 4.0 International license .

267 Statistics

268 Mean ± standard deviation was used to summarize normally distributed continuous variables, and median (with 25th-75th percentiles) was used for non-normal distribution or non-continuous 269 270 ordinal data. Categorical variables are presented as number (%). A priori, six anatomical and 271 pathophysiological subgroups were established by firstly dividing the cohort into those with and 272 without prior significant ventricular pacing (defined as Vp>40% prior to CRT), and then further 273 subdividing into three anatomical subgroups: those without CHD, those with CHD with two 274 ventricles and systemic LV, and those with other ('complex') CHD. Between-group variation was 275 quantified using one-way ANOVA for normally distributed variables and Kruskall-Wallis for non-276 normal/categorical variables. 277 278 Ordinal logistic regression was used to assess the association of indices with ordinal outcomes 279 (worse/no change/improved absolute or proportional change in SVEF). Multivariable modelling 280 used a stepwise approach taking forward parameters with p<0.05 on univariable analysis. 281 Multivariable modelling was performed without inclusion of the subgroup 1-6 variable on 282 account of collinearity, except on direct assessment of the significant subgroups. Longitudinal 283 measures were evaluated using multilevel mixed-effects linear regression modeling with cubic

284 model for estimation of pacing effect and visualized using fractional polynomial plot with 95%

285 Cls. Statistics were analyzed using Stata (version 18.0, Stata Corp LP, College Station, Texas).

It is made available under a CC-BY-NC-ND 4.0 International license .

287 Results

288 Subjects

289 Baseline characteristics are delineated in Table 1. A total of 167 eligible CRT subjects were

- identified, of whom 105 (63%) were V-paced>40% at final follow-up prior to commencement of
- 291 CRT. 122 (73%) had congenital heart disease, the majority of whom (85 (70%)) had a
- 292 biventricular circulation with systemic LV. A structural surgical procedure was performed within
- 293 30days before or after the implant of the CRT system in 34 (20%) subjects, 29 (85%) of which
- 294 were at the same procedure.
- 295
- 296 Between the 6 pre-defined subgroups, several trends in baseline indices were noted. Those
- with prior pacing (Groups 1, 2 and 3) had a very high median pacing percentage (100% [100-
- 298 100%]). Compared to the non-paced cohorts (Groups 4,5 and 6) they were similar in age at
- enrollment (9.8 [3.8-20] years versus 14.9 [9.2-20] years, p=0.13) and had similar SVEF
- 300 (30.8±8.9% versus 31.8±8.5%, p=0.49), but tended to have wider QRSd at baseline (165±26ms
- 301 versus 149±28ms, p=0.0003).
- 302

303 CRT delivery was good throughout follow-up with median pacing percentage 100% [100-100%] 304 at all follow-up time points. Follow-up was recorded close to the target dates of 6months post 305 implant (actual timing 5.8months [4.1-6.7months] post implant), 12 months (12.4months [11.1-306 13.9months]), 5 years (5.0 [4.7-5.4years]) and latest follow-up (5.1 years [2.0-8.6 years]).

- 306 307
- 308

309 Response Definition 1: Improvement in SVEF within the First Year Post-CRT

310

311 *Response to CRT*

- 312 Formal assessment of SVEF was available for 150 (90%) subjects for at least one of the
- 313 stipulated 6 month or 12 month time points. 90 (60%) had follow-up available at both time
- points, with excellent intraclass correlations between the SVEF measurements made at the two

It is made available under a CC-BY-NC-ND 4.0 International license .

- time points (average ICCs, two-way mixed effects, absolute agreement: SVEF 0.91 (95% CI 0.86-
- 316 0.94)). Average values were taken for those with two follow-up measurements.
- 317
- Across all subjects with formal SVEF measurements, 96 (64%) exhibited an improvement in
- absolute SVEF >5% and 110 (73%) a proportional improvement in SVEF >10% (Table 2 and
- 320 Figure 2). Overall, there was an median increase in SVEF of 11% [3-21%] (p<0.001 compared to
- baseline), and a decrease in QRS duration (18±24msec, p<0.001), QRSd z-score (1.9±2.4,
- 322 p<0.001) and NYHA class (0.6±1 lower, p<0.001), but no change in number of HF medications
- 323 (0.04±0.92, p=0.63). Between subgroups, there was minimal variation in degree of change of
- 324 clinical parameters, except for QRSd and QRSd z-score, which shortened more in the prior
- paced groups (delta of 22±21ms versus 8±25ms, p<0.001 and delta of 2.5±2.1 versus 1.0±2.5,
- 326 p<0.001, respectively).
- 327

328 There was minimal correlation between change in EF and change in QRSd (p=0.10, R²=0.01) or

- 329 QRSd z-score (p=0.044, R²= 0.03), suggesting that the crude shortening of QRSd was not highly
- 330 significant in determining EF improvement following CRT. Improvement in EF was more strongly
- 331 correlated with improvement in NYHA class (p<0.001, $R^2=0.12$).
- 332
- 333
- 334 Morphological and pathophysiological predictors of response
- Factors associated with the response to CRT by ordinal logistic regression are shown in Table 3.
- 336 The pathophysiological groups 1-5 were not significantly associated with response, and only
- 337 Group 6 (no prior pacing, complex CHD) differed significantly from the other groups. This group
- 338 was least likely to demonstrate a response to CRT in terms of either an absolute (coefficient -
- 339 2.2 [-3.6 -0.8), p=0.002) or proportional response (coefficient -1.4 [-2.9 -0.03), p=0.046).
- 340
- 341 Other predictors of response differed between the absolute and proportional SVEF
- 342 improvement assessments. On analysis of predictors of absolute SVEF improvement (>5% rise
- in SVEF), patients with lower baseline SVEF were more likely to experience a beneficial

It is made available under a CC-BY-NC-ND 4.0 International license .

- response, on both univariable and multivariable analysis. Those with biventricular circulation,
- 345 systemic LV, CDtoLWSV and lower lead separation ratio were more likely to respond on
- 346 univariable but not multivariable analysis.
- 347
- 348 On assessment of predictors of proportional improvement in SVEF, a lower SVEF was again a
- 349 significant predictor on univariable and multivariable response, as was CDtoLWSV.
- 350
- 351 The association of SVEF and response (absolute and proportional) is demonstrated in Figure 3.
- 352 The coefficient for response was significantly worse for those with higher SVEF. All higher SVEF
- 353 groups were associated with significantly lower response coefficient (p<0.05) on absolute
- response, with the exception of the 3rd tertile (36/45%) and 4th quintile (36/40%). All higher
- 355 SVEF groups were associated with significantly lower response coefficient on proportional
- response, with the exception of the 2^{nd} quartile (25/31%).
- 357
- 358
- **359** Response Definition 2: Longitudinal Improvement in Parameters versus Control Groups
- **360** *Response to CRT*
- Across the whole cohort (139 propensity matched pairs, total 278 subjects), there was a clear longitudinal impact of CRT upon SVEF (CRT coefficient 4.0 (1.9-6.1), p<0.001) and QRS duration z-score (-0.7 (-1.2- -0.2), p=0.015). There was no significant CRT-associated longitudinal impact upon NYHA class, total number of HF medications, or somatic growth (in terms of weight or height). There remained no association of CRT with somatic growth on subanalysis of subjects prior to age 18years (192 PSM subjects, Height: 493 measurements, CRT coefficient 1.02 (-8.7-11), p=0.84); Weight: 507 measurements, CRT coefficient 0.95 (-6.4-8.3), p=0.80).
- 368
- 369 Morphological and pathophysiological predictors of response
- 370 Longitudinal change in SVEF was assessed within the primary binary subgroups [with/without
- 371 pacing, with/without CHD, with/without biventricular circulation, with systemic LV or RV]. A
- 372 significant positive association of SVEF with CRT was seen in 6 of the 8 subgroups (75%) (Figure

It is made available under a CC-BY-NC-ND 4.0 International license .

- 4). The relationship between CRT and longitudinal SVEF was not significant in patients with a
- 374 systemic RV, those who were not paced prior to enrollment, and in subgroups with small
- 375 numbers.
- 376

377 Sensitivity analyses

- 378 Excluding subjects who underwent concurrent surgical procedures within 30days either side of
- 379 CRT implant (n=34), overall change in SVEF was similar at +10% [3-21%] across all 118 subjects
- 380 with early formal SVEF assessment. 74 (63%) were responders in terms of absolute
- improvement in SVEF and 87 (74%) were responders in terms of proportional improvement in
- 382 SVEF. Significant univariable and multivariable predictors of response remained unchanged,
- 383 except that CDtoLWSV was now a significant predictor of absolute response on multivariable
- analysis (0.93 [0.06-1.83], p=0.032) as well as univariable. On longitudinal analysis of PSM
- 385 subjects and controls (252 PSM subjects, 830 measurements), SVEF remained significantly
- associated with CRT (CRT coefficient 2.7 (0.2-5.2), p=0.038).

It is made available under a CC-BY-NC-ND 4.0 International license .

388								
389								
390	Discussion							
391	This study assessed the response to CRT in a large multicenter retrospective cohort of children							
392	and patients with CHD. Two measures of response were assessed. One measure used the CRT							
393	recipient as their own control, defining response as an improvement in SVEF in the medium							
394	term at 6-12months. The second measure used a tightly matched control cohort of non-CRT							
395	patients, and compared the longitudinal trajectories of the patients with and without CRT. The							
396	main findings are:							
397								
398	Medium-term improvement in SVEF from baseline							
399	\circ A majority of subjects responded to CRT, with responders identified within all							
400	subgroups							
401	\circ Those with low baseline EF or conduction delay to the lateral wall of the systemic							
402	ventricle (for example, LBBB in a structurally normal heart) were most likely to							
403	respond.							
404	• Those without prior ventricular pacing <u>and</u> with 'complex' CHD were less likely to							
405	respond							
406	 QRS duration was not associated with response 							
407	Improved long-term trajectory versus controls							
408	\circ CRT was associated with a general improvement in SVEF and shortening of QRS							
409	duration							
410	\circ Most binarised subgroups demonstrated an improvement in SVEF with CRT							
411	\circ Those with systemic RV and those without pacing prior to enrollment did not							
412	demonstrate a significantly improved SVEF trajectory compared to controls							
413								
414								

It is made available under a CC-BY-NC-ND 4.0 International license .

415 Patient Anatomical and Pathological Variants

416 By the nature of the patient cohort, there was considerable heterogeneity between each 417 subject. Each subject presents a unique constellation of patient-specific factors, all of which 418 may impact upon CRT response. There is a constant pull between the desire to define the 419 patient groups as homogenously as possible versus the obligation to avoid creating ever smaller 420 divisions that preclude the possibility of meaningful comparison. The six groups were designed 421 to map onto those patient groups that have been defined in prior studies to be potentially good or poor responders to CRT.¹¹ These include pacing-induced cardiomyopathies, systemic LVs, 422 systemic RVs and univentricular circulations ^{7-9, 20, 21}. 423

424

425 Highest Likelihood of Response

The absence of consistent significant associations between most of the anatomical and pathological groups and subsequent response to CRT is a significant finding. On assessment of early response (using the patient as their own baseline), the most consistent finding was that patients with lower SVEF tended to be most likely to demonstrate not only a proportional response, but also an absolute response (>5% improvement). This suggests that there may not be a clear cutoff to define when CRT is 'too late', and that even those with severely impaired function may experience an increase in SVEF with CRT.

433

434 Conduction delay to the lateral wall of the systemic ventricle was also a parameter that was 435 significant on univariable analysis of absolute response, and both univariable and multivariable 436 analysis of proportional response. This measure was selected as analogous to LBBB in the 437 functionally normal heart, and may be an important indicator in more complex hearts. Further 438 research is required to assess whether this is associated with epiphenomena such as classical pattern dyssynchrony in the CHD population.²² However, the fact that it was rarely seen in the 439 complex CHD groups (16% of subjects), and yet the response rate in those groups was 40-60%, 440 441 suggests that this relatively crude index of electrical activation is a useful but not an essential 442 criterion for response to CRT.

443

It is made available under a CC-BY-NC-ND 4.0 International license .

In contrast to many non-CHD adult CRT studies, it was notable that increased QRSd alone was
not associated with response by any measure. Some of this difference may be accounted for by
the heterogeneity of interventricular conduction delays, but the most significant fact is likely
that the vast majority of recipients had a 'sufficient' degree of electrical dyssynchrony. 156
(93%) had a QRSd z-score>3.55 (the cutoff employed as a marker of equivalency for strict LBBB
criteria), and 145 (87%) had QRSd z-score >4.8, the equivalent to around 150msec and the
longest QRSd cutoff evaluated in major conventional CRT trials.

451

452 Lower Likelihood of Response

On longitudinal assessment versus controls, patients without prior ventricular pacing and those
with systemic RV did not demonstrate a superior outcome with CRT (Figure 4). This trend was
also reflected in the lower medium-term response rates in the group with no prior pacing, and
CHD without a biventricular, systemic LV, circulation. Again, in such a heterogenous group,
identifying the underlying reasons for these findings is challenging, but a number of factors may
be postulated.

459

460 CRT in Patients without Biventricular Circulation

461 Increasingly, large studies have demonstrated that ventricular pacing of the single ventricle patient is highly deleterious to long term survival, but no study has identified a clear 462 improvement in outcome with CRT.^{23, 24} At least in part, this is likely related to the limited 463 464 number of single ventricle patients receiving CRT systems. Numbers in this study remain 465 relatively small, but nevertheless, we identified a significant impact of CRT on long-term SVEF 466 trends. The second response outcome of the study, longitudinal trends versus matched 467 controls, assists determining whether differing responses to CRT are related to weaker effect of 468 CRT or the higher overall risk of deterioration in specific patient groups. In this context, there is 469 an argument that, for patients with a single ventricle, the absence of deterioration may itself be 470 a good response to CRT, and this would explain the discrepancy between the univariable 471 findings of medium-term response (where there is a trend to better CRT response in

It is made available under a CC-BY-NC-ND 4.0 International license .

- 472 biventricular patients) and the longitudinal response versus controls. A similar trend in the
- 473 single ventricle population has been demonstrated previously by the Boston group.²⁵
- 474

475 CRT in Patients with Systemic Right Ventricle

476 The other major anatomical subgroup that has received individual attention in most prior 477 studies is patients with systemic RV. Published results in this cohort have been mixed at best. While some studies have found an attenuated response to CRT^{8, 9, 26}, others showed no 478 response.^{7, 21} A recent metanalysis found a marginally inferior response in the systemic RV 479 population.¹¹ Our study again found a mixed picture. On medium-term SVEF response, there 480 481 was a weak (univariable only) trend towards poorer response to CRT, while on longitudinal 482 outcome versus controls there was no significant CRT effect. These findings may be partially 483 attributed to challenges in measuring the EF of the systemic RV, and the latter finding may 484 relate predominantly to sample size (Figure 4). As such, these findings certainly do not suggest 485 that CRT is contraindicated in the systemic RV population, but there is at least weaker evidence 486 of efficacy.

487

488 Clinical Implications

This study has demonstrated that CRT results in a clear improvement in SVEF in many pediatric
and CHD patients, with responders identified in all anatomical and pathophysiological subtypes.

492 However, CRT remains a complex intervention with significant risks anticipated both at the time 493 of implant (particularly in those requiring repeat sternotomy) and in a life-time of device 494 management. Therefore, indices to identify those who are most likely to respond remain 495 helpful in weighing risk and benefit. On assessment of both medium-term change in SVEF and 496 longitudinal trajectory versus controls there are significant trends that should be noted. Based 497 upon this data, those with lower SVEF, those with electrical conduction delay to the lateral wall 498 of the systemic ventricle (such as LBBB in those with conventional ventricular orientation) and 499 those with systemic LV are most likely to experience a medium and long-term response.

500

It is made available under a CC-BY-NC-ND 4.0 International license .

501 Limitations

This was a multicenter retrospective study, and as such the delineation of a clinical response to CRT is highly challenging. We have attempted to be as comprehensive as possible, using two outcome measures, one indexed to the patient and one to a tightly matched control group. It is also established that SVEF alone is not the only marker of response, and prospective studies would be significantly enhanced by the formal evaluation of baseline parameters such as cardiopulmonary metabolics and laboratory studies such as BNP or NT-proBNP.

508

509 We chose to include patients with concurrent surgery in the main analyses. Many of these

510 surgical procedures were on the subpulmonary ventricle, but nonetheless, there are inevitably

511 hemodynamic implications for the systemic ventricle and general clinical condition resulting

512 from all structural surgical interventions. Sensitivity analyses suggested a similar result for the

513 main clinical analyses.

514

In a similar vein, in common with all major studies of CRT in these patient cohorts, the pediatric and CHD groups have been amalgamated for many of the analyses. HF in pediatric patients without CHD represents a very different pathology to HF in those with CHD, and there is an argument that they should be assessed entirely separately. However, the numbers of patients in each subgroup were small and we have generally aimed for a robust assessment on multivariable analysis to assess and quantify the role of contributing factors.

521

522 Conclusions

523 CRT in children and patients with CHD frequently results in an improvement in SVEF. This study 524 suggests that all the major anatomical and pathophysiological subgroups have the potential to 525 respond to CRT. However, those with lower SVEF, those with electrical conduction delay to the 526 lateral wall of the systemic ventricle (such as LBBB in those with conventional ventricular 527 orientation), and those with systemic LV are most likely to experience a medium- and long-term 528 response.

It is made available under a CC-BY-NC-ND 4.0 International license .

529 References

530

Epstein AE, DiMarco JP, Ellenbogen KA, Estes Iii NAM, Freedman RA, Gettes LS, Gillinov
 AM, Gregoratos G, Hammill SC and Hayes DL. 2012 ACCF/AHA/HRS Focused Update of the 2008
 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. *Circulation Journal*.
 2013;127:e283-352.

Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M,
 Clavell AL, Hayes DL, et al. Cardiac Resynchronization in Chronic Heart Failure. *New England Journal of Medicine*. 2002;346:1845-1853.

Bristow MR, Saxon LA, Boehmer JP, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L,
 DeMets D, White BG, et al. Cardiac resynchronization therapy with or without an implantable
 defibrillator in advanced chronic heart failure. *New England Journal of Medicine*.

541 2004;350:2140-50.

Linde C, Abraham WT, Gold MR, St. John Sutton M, Ghio SDaubert C. Randomized Trial
 of Cardiac Resynchronization in Mildly Symptomatic Heart Failure Patients and in Asymptomatic
 Patients With Left Ventricular Dysfunction and Previous Heart Failure Symptoms. *Journal of the American College of Cardiology*. 2008;52:1834-1843.

Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes Iii NAM, Foster E,
 Greenberg H, Higgins SL, et al. Cardiac-Resynchronization Therapy for the Prevention of Heart Failure Events. *New England Journal of Medicine*. 2009;361:1329-38.

Tang ASL, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol
 G, Birnie DH, Sapp JL, et al. Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart
 Failure. *New England Journal of Medicine*. 2010;363:2385-2395.

Dubin AM, Janousek J, Rhee E, Strieper MJ, Cecchin F, Law IH, Shannon KM, Temple J,
 Rosenthal E, Zimmerman FJ, et al. Resynchronization Therapy in Pediatric and Congenital Heart
 Disease Patients. J Am Coll Cardiol. 2005;46:2277-2283.

Janoušek J, Gebauer RA, Abdul-Khaliq H, Turner M, Kornyei L, Grollmuß O, Rosenthal E,
 Villain E, Früh A, Paul T, et al. Cardiac resynchronisation therapy in paediatric and congenital
 heart disease: Differential effects in various anatomical and functional substrates. *Heart*.
 2009;95:1165-1171.

559 9. Cecchin F, Frangini Pa, Brown DW, Fynn-Thompson F, Alexander ME, Triedman JK, 560 Gauvreau K, Walsh EP and Berul CI. Cardiac resynchronization therapy (and multisite pacing) in 561 pediatrics and congenital heart disease: five years experience in a single institution. *Journal of* 562 *cardiovascular electrophysiology*. 2009;20:58-65.

563 10. Chubb H, Rosenthal DN, Almond CS, Ceresnak SR, Motonaga KS, Arunamata AA, Long J,
564 Trela AV, Hanisch D, McElhinney DB and Dubin AM. Impact of Cardiac Resynchronization
565 Therapy on Heart Transplant-Free Survival in Pediatric and Congenital Heart Disease Patients.

566 *Circ Arrhythm Electrophysiol*. 2020;13:e007925.

567 11. Tokavanich N, Mongkonsritragoon W, Sattawatthamrong S, Techasatian W, Siranart N,

568 Prasitlumkum N, Navaravong L and Chokesuwattanaskul R. Outcomes of cardiac

resynchronization therapy in congenital heart disease: A meta-analysis and systematic review. *J*

570 Cardiovasc Electrophysiol. 2024;35:249-257.

571 12. Chubb H, Mah D, Shah M, Lin KY, Peng D, Hale B, May LJ, Etheridge SP, Goodyer W,

572 Ceresnak S, et al. Multicenter Study of Survival Benefit of Cardiac Resynchronization Therapy in
 573 Pediatric and Congenital Heart Disease. *JACC Electrophysiology*. 2024.

13. Rickard J, Michtalik H, Sharma R, Berger Z, Iyoha E, Green AR, Haq N and Robinson KA.

575 Predictors of response to cardiac resynchronization therapy: A systematic review. *Int J Cardiol*.
576 2016;225:345-352.

577 14. Schiller O, Dham N, Greene EA, Heath DM, Alexander MEBerul CI. Pediatric dilated
578 cardiomyopathy patients do not meet traditional cardiac resynchronization criteria. *Journal of*579 *Cardiovascular Electrophysiology*. 2015;26:885-889.

580 15. Chubb HMotonaga KS. Cardiac resynchronization and implantable defibrillators in adults 581 with congenital heart disease. *Heart Fail Rev.* 2020;25:657-670.

582 16. Strauss DG, Selvester RHWagner GS. Defining left bundle branch block in the era of 583 cardiac resynchronization therapy. *Am J Cardiol*. 2011;107:927-34.

584 17. Prineas R, Crow RH B. *The Minnesota Code Manual of Electrocardiographic Findings*585 *Standards and Procedures for Measurement and Classification*. London: John Wright/PSG Inc;
586 1982.

587 18. Anavekar NS, Gerson D, Skali H, Kwong RY, Yucel EKSolomon SD. Two-dimensional
588 assessment of right ventricular function: an echocardiographic-MRI correlative study.
589 *Echocardiography*. 2007;24:452-6.

590 19. Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos P, Merlino J, Abraham WT, Ghio 591 S, Leclercq C, Bax JJ, et al. Results of the predictors of response to CRT (PROSPECT) trial.

592 *Circulation*. 2008;117:2608-2616.

593 20. Flugge AK, Wasmer K, Orwat S, Abdul-Khaliq H, Helm PC, Bauer U, Baumgartner H, Diller
594 GP and German Competence Network for Congenital Heart Defects I. Cardiac resynchronization
595 therapy in congenital heart disease: Results from the German National Register for Congenital
596 Heart Defects. *Int J Cardiol.* 2018;273:108-111.

597 21. Koyak Z, de Groot JR, Krimly A, Mackay TM, Bouma BJ, Silversides CK, Oechslin EN, Hoke
598 U, van Erven L, Budts W, et al. Cardiac resynchronization therapy in adults with congenital heart
599 disease. *Europace*. 2018;20:315-322.

600 22. Risum N, Jons C, Olsen NT, Fritz-Hansen T, Bruun NE, Hojgaard MV, Valeur N, Kronborg

601 MB, Kisslo J and Sogaard P. Simple regional strain pattern analysis to predict response to

602 cardiac resynchronization therapy: Rationale, initial results, and advantages. *American Heart* 603 *Journal*. 2012;163:697-704.

Poh CL, Celermajer DS, Grigg LE, Kalman JM, McGuire MA, Gentles TL, Radford DJ,
Bullock A, Disney PJS, Winlaw D, et al. Pacemakers are associated with a higher risk of late
death and transplantation in the Fontan population. *Int J Cardiol*. 2019;282:33-37.

607 24. Bulic A, Zimmerman FJ, Ceresnak SR, Shetty I, Motonaga KS, Freter A, Trela AV, Hanisch

608 D, Russo L, Avasarala K and Dubin AM. Ventricular pacing in single ventricles—A bad 609 combination. *Heart Rhythm*. 2017;14:853-857.

610 25. O'Leary ET, Gauvreau K, Alexander ME, Banka P, Bezzerides VJ, Fynn-Thompson F,

611 Triedman JK, Walsh EP and Mah DY. Dual-Site Ventricular Pacing in Patients With Fontan

612 Physiology and Heart Block: Does it Mitigate the Detrimental Effects of Single-Site Ventricular

613 Pacing? *JACC Clin Electrophysiol*. 2018;4:1289-1297.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 614 26. Sakaguchi H, Miyazaki A, Yamada O, Kagisaki K, Hoashi T, Ichikawa HOhuchi H. Cardiac
- 615 Resynchronization Therapy for Various Systemic Ventricular Morphologies in Patients With
- 616 Congenital Heart Disease. *Circulation Journal*. 2015;79:649-655.

It is made available under a CC-BY-NC-ND 4.0 International license .

618 Tables

		Ventricularly Paced Pre-Enrollment (Vp>40%)			No Significant Enrollment			
	All	Group 1: Non-CHD	Group 2: BiV circ with sys LV	Group 3: Complex CHD	Group 4: Non-CHD	Group 5: BiV circ with sys LV	Group 6: Complex CHD	p-value (R ²)
	n=167	n=27	n=58	n=20	n=18	n=27	n=17	
Age (years)	12 [4.3-20]	4.4 [0.8- 17]	11.3 [7.2- 21]	13.6 [5.2- 33]	14.4 [9.2- 16]	15 [9.7-24]	18.3 [8.1- 22]	0.008 (0.06)
Male sex (n)	95 (57%)	12 (44%)	32 (55%)	9 (45%)	10 (56%)	22 (81%)	10 (59%)	0.09 (0.03)
Race (non-white, n)	23 (14%)	5 (19%)	8 (14%)	0 (0%)	3 (17%)	5 (19%)	2 (12%)	(0.03)
Weight (kg)	45.9 (+/- 34.1)	35.2 (+/- 36.7)	43.2 (+/- 27.9)	44.5 (+/- 28.3)	51.4 (+/- 41.9)	57.5 (+/- 42.9)	49.2 (+/- 28)	0.23 (0.01)
SV EF (%)	31.2 (+/- 8.8)	29.8 (+/- 10.2)	31.4 (+/- 8.7)	30.7 (+/- 8.2)	29.2 (+/-8.6)	32.1 (+/- 9.7)	34.1 (+/- 5.7)	0.56 (0.02)
Cardiomyopathy (n)	48 (29%)	16 (59%)	10 (17%)	0 (0%)	18 (100%)	3 (11%)	1 (6%)	<0.001 (0.44)
QRS Duration (msec)	159 (+/-28)	154 (+/-33)	169 (+/-19)	169 (+/-27)	140 (+/-28)	156 (+/-31)	148 (+/-23)	<0.001 (0.10)
QRS Duration z-score	7.4 (+/-2.7)	8 (+/-2.3)	8.4 (+/-2.4)	8.2 (+/-2.7)	5.6 (+/-3)	6.5 (+/-2.5)	5.9 (+/-2.1)	<0.001 (0.14)
Conduction Delay to Lateral Wall of SV (n)	69 (41%)	11 (41%)	27 (47%)	2 (10%)	10 (56%)	15 (56%)	4 (24%)	0.01 (0.06)
NYHA Class	2 [1.5-3]	2 [1-3]	2 [1.5-3]	2 [2-3]	3 [3-3]	2 [1-2]	2 [1.5-3]	0.04 (0.05)
Transplant	7 (4%)	1 (4%)	0 (0%)	2 (10%)	2 (11%)	1 (4%)	1 (6%)	0.26 (0.01)
HF medications (n, total)	3 [2-4]	2 [1-4]	2 [1-3]	3 [2-4]	3 [2-4]	3 [1-4]	3 [3-3]	0.23 (0.01)
Arrhythmia meds (n, total)	0 [0-1]	0 [0-1]	0 [0-1]	0 [0-0]	1 [0-1]	0 [0-1]	1 [0-2]	0.27 (0.01)
Genetic/metabolic condition	29 (17%)	2 (7%)	16 (28%)	2 (10%)	3 (17%)	5 (19%)	1 (6%)	0.13 (0.02)
Pre-CRT Device	T	T		1	1		1	-0.001
РРМ	103 (62%)	26 (96%)	56 (97%)	19 (95%)	0 (0%)	1 (4%)	1 (6%)	<0.001 (0.85)
ICD	8 (5%)	0 (0%)	1 (2%)	1 (5%)	2 (11%)	2 (7%)	2 (12%)	0.27 (0.01)
Vp pre CRT	100 [0-100]	100 [100- 100]	100 [100- 100]	100 [100- 100]	0 [0-0]	0 [0-0]	0 [0-0]	0.63* (0.01)
CRT Device		•						1
Transvenous	49 (29%)	5 (19%)	13 (22%)	4 (20%)	12 (67%)	10 (37%)	5 (29%)	0.004 (0.07)
Epicardial	109 (65%)	21 (78%)	40 (69%)	15 (75%)	5 (28%)	17 (63%)	11 (65%)	0.013 (0.06)
Hybrid	9 (5%)	1 (4%)	5 (9%)	1 (5%)	1 (6%)	0 (0%)	1 (6%)	0.73 (0.01)
CRT-D	43 (26%)	2 (7%)	11 (19%)	5 (25%)	10 (56%)	10 (37%)	5 (29%)	(0.07)
Concurrent Surgery at Time of CRT Implant								
Same procedure	29 (17%)	0 (0%)	10 (17%)	5 (25%)	2 (11%)	11 (41%)	1 (6%)	0.002 (0.09)
<30days	5 (3%)	0 (0%)	2 (3%)	0 (0%)	0 (0%)	3 (11%)	0 (0%)	0.12 (0.03)

619 Table 1. Baseline Demographics. BiV: biventricular, SV EF: systemic ventricle ejection fraction,

620 NYHA: New York Heart Association, HTX: heart transplant listing prior to implant, HF: heart

621 failure, PPM: permanent pacemaker, Vp: ventricular pacing, CRT-D: cardiac resynchronization

622 therapy-defibrillator.

It is made available under a CC-BY-NC-ND 4.0 International license .

623

	All	Ventricularly Paced			No Signifi	p-		
		Group 1:	Group 2:	Group 3:	Group 4:	Group 5:	Group	value
		Non-CHD	BiV circ	Other	Non-	BiV circ with	6:	(R ²)
			with sys LV	CHD	CHD	sys LV	Other	
							CHD	
	n=150	n=24	n=52	n=18	n=17	n=24	n=15	
Absolute Change in Systemic Ventricular Ejection Fraction								
Improved	96 (64%)	19 (79%)	34 (65%)	9 (50%)	10 (59%)	20 (83%)	4	0.005
(>5%)							(27%)	(0.08)
No change	26 (17%)	2 (8%)	9 (17%)	5 (28%)	4 (24%)	2 (8%)	4	
(0-5%)							(27%)	
Worse	28 (19%)	3 (13%)	9 (17%)	4 (22%)	3 (18%)	2 (8%)	7	
(<0%)							(47%)	
Proportional Ch	nange in Syste	emic Ventricu	ular Ejection F	raction				
Improved	110 (73%)	19 (79%)	38 (73%)	12 (67%)	13 (76%)	20 (83%)	8	0.15
(>10%)							(53%)	(0.05)
No change	12 (8%)	2 (8%)	5 (10%)	2 (11%)	1 (6%)	2 (8%)	0 (0%)	
(0-10%)								
Worse	28 (19%)	3 (13%)	9 (17%)	4 (22%)	3 (18%)	2 (8%)	7	
(<0%)							(47%)	
Change in Clinic	cal Parameter	rs following C	RT	•		•		
Increase in	11 [3-21]	18 [10-	11 [3-19]	10 [1-23]	7 [5-16]	15 [7-20]	5 [-5-	0.09
SVEF (%)		26]					17]	(0.03)
Decrease in	18 (+/-24)	22 (+/-20)	23 (+/-22)	22 (+/-	0 (+/-27)	9 (+/-21)	15 (+/-	0.005
QRS duration				22)			29)	(0.08)
(ms)								
Decrease in	1.9 (+/-	2.5 (+/-2)	2.5 (+/-2.2)	2.4 (+/-	0.3 (+/-	1.1 (+/-2.2)	1.6	0.005
QRS duration	2.4)			2.2)	2.7)		(+/-	(0.11)
z-score							2.8)	
Decrease in	0.04 (+/-	0.02 (+/-	0.15 (+/-	0.05 (+/-	-0.06	-0.04 (+/-	-0.14	0.88
number HF	0.92)	0.77)	0.97)	0.85)	(+/-1.03)	1.1)	(+/-	(0.02)
meds (n)							0.57)	
Decrease in	0.6 (+/-1)	0.8 (+/-	0.7 (+/-0.9)	0.6 (+/-	0.9 (+/-	0.4 (+/-0.8)	0.4	0.53
NYHA Class		1.3)		0.7)	0.9)		(+/-1)	(0.03)
Death or	15 (9%)	1 (4%)	3 (5%)	4 (20%)	4 (22%)	0 (0%)	3	0.02
transplant							(18%)	(0.08)
within 1 year								

624 Table 2. Response to CRT by Subgroup. Please see methods for definitions of improvement/no

625 change/worsening of primary Endpoints. p-value is one-way ANOVA, grouped by the six

626 subtypes.

627

It is made available under a CC-BY-NC-ND 4.0 International license .

	Absolute Change in Systemic Ventricular Eiection Fraction				Proportional Change in Systemic Ventricular Ejection Fraction			
	Univariable		Multivariable		Univariable		Multivariable	
		p-		p-		p-		p-
	Coef	value	Coef	value	Coef	value	Coef	value
	-0.02 (-0.04-						-0.01 (-	
Age (years)	0)	0.062			-0.02 (-0.04-0)	0.041	0.03-0.02)	0.567
	-0.33 (-0.99-				-0.81 (-1.58		-0.64 (-	
Sex (male)	0.32)	0.32			0.05)	0.038	1.51-0.24)	0.153
	0.38 (-0.7-				-0.02 (-1.11-			
Race (non-white)	1.46)	0.49			1.06)	0.97		
	-0.01 (-0.02-							
Weight (kg)	0)	0.2			-0.01 (-0.02-0)	0.25		
Systemic Ventricle EF	-0.05 (-0.09		-0.05 (-0.09-		-0.08 (-0.12		-0.08 (-	
(%)	0.01)	0.013	0)	0.039	0.03)	0.001	0.130.02)	0.006
	-0.22 (-0.91-				-0.39 (-1.14-			
Cardiomyopathy (n)	0.48)	0.55			0.36)	0.31		
	1.07 (0.15-		0.86 (-0.16-		0.53 (-0.53-			
Biventricular Circulation	1.99)	0.022	1.88)	0.1	1.59)	0.33		
	0.96 (0.14-		0.4 (-0.56-		0.64 (-0.27-			
Systemic LV	1.78)	0.021	1.35)	0.417	1.55)	0.17		
Congenital Heart	-0.41 (-1.17-				-0.35 (-1.2-			
Disease	0.35)	0.29			0.49)	0.41		
	0.24 (-0.43-				0.07 (-0.67-			
Prior pacing (Vp>40%)	0.91)	0.48			0.81)	0.86		
	-0.01 (-0.02-						-0.02 (-	
QRS duration (ms)	0)	0.11			-0.02 (-0.03-0)	0.037	0.03-0)	0.061
	-0.04 (-0.17-				-0.06 (-0.2-			
QRS duration z-score	0.08)	0.51			0.08)	0.41		
Conduction delay to Lat	0.94 (0.23-		0.7 (-0.03-		1.21 (0.36-		1.28 (0.36-	
Wall SV	1.66)	0.01	1.50)	0.059	2.07)	0.006	2.2)	0.006
	-3.47 (-6.86		-3.06 (-6.66-		-3.65 (-7.34-			
Lead Separation Ratio	0.09)	0.044	0.55)	0.097	0.04)	0.053		
	-0.11 (-0.49-				-0.04 (-0.47-			
NYHA Class	0.27)	0.58			0.38)	0.84		
Number of HF	-0.11 (-0.35-				-0.01 (-0.28-			
Medications (n)	0.13)	0.37			0.26)	0.94		
Genetic/Metabolic	0.41 (-0.48-				-0.02 (-0.92-			
Disorder	1.29)	0.37			0.87)	0.96		
Subtype 1	NA	NA			NA	NA		
	-0.67 (-1.8-				-0.34 (-1.49-			
Subtype 2	0.47)	0.25			0.81)	0.56		
	-1.21 (-2.51-				-0.64 (-2.01-			
Subtype 3	0.1)	0.071			0.73)	0.36		
	-0.89 (-2.24-				-0.2 (-1.68-			
Subtype 4	0.47)	0.2			1.29)	0.8		
	0.3 (-1.15-				0.29 (-1.16-			
Subtype 5	1.76)	0.68			1.73)	0.7		
	-2.2 (-3.57		-1.4 (-2.4	0.008	-1.44 (-2.86		-6.5 (-2.5-	
Subtype 6	0.83)	0.002	0.4)*	*	0.03)	0.046	-0.2)'	0.021

Table 3. Association of baseline characteristics and change in systemic ventricular ejection

630 fraction following CRT. Ordinal logistic regression, with categories as defined in methods.

631 * For the multivariable analysis of Subgroup 6, Systemic LV and biventricular circulation were

632 excluded due to collinearity

It is made available under a CC-BY-NC-ND 4.0 International license .



634 Figure 1. Measurement of separation of the ventricular leads. Top row- endovascular system,

635 bottom row-epicardial system.

It is made available under a CC-BY-NC-ND 4.0 International license .



637 Figure 2. Change in systemic ventricular ejection fraction with time from CRT implant (split x-

638 axis). CHD: congenital heart disease, BiV: biventricular, SysLV: systemic left ventricle. Best fit

639 *line calculated using cubic regression.*

It is made available under a CC-BY-NC-ND 4.0 International license .



640

641 *Figure 3. (Upper) Frequency histogram of systemic ventricle ejection fraction (SVEF) at baseline.*

642 (Lower) Coefficient for response (ordinal regression) versus lowest quintile/quartile/tertile for

643 absolute SVEF response (Abs) and proportional SVEF response (Prop). Upper and lower tertile

644 cutoffs were 10/28%, 28/35% and 36/45%, respectively. Quartile cutoffs were 10/25%, 25/31%,

645 31/37% and 37/45%. Quintile cutoffs were 10/24%, 24/30%, 30/35%, 36/40%, and 40/45%.

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 4. Longitudinal plots presenting the long-term trajectory of systemic ventricle ejection
fraction (SVEF) within the eligible propensity score matched (PSM) cohorts with and without
CRT. Separate PSM was performed for each subanalysis. Plots are fractional polynomial plots

It is made available under a CC-BY-NC-ND 4.0 International license .

- 650 and the pacing effect is estimated using multilevel mixed-effects linear regression modeling with
- 651 *cubic model.*